How Tirzepatide Activates Two Receptors at Once: A Molecular-Level Explanation

Molecular dynamics simulations revealed how tirzepatide activates both the GLP-1 and GIP receptors. The receptor activation involves a closure-to-open transition in the extracellular domain and movement of transmembrane helices — similar to how simpler class A receptors activate. Tirzepatide's conserved residues bind similarly to both receptors, but mutations in non-conserved residues create a biased binding pattern: C-terminal mutations weaken binding to GLP-1R, while N-terminal mutations strengthen binding to GIPR. This explains tirzepatide's dual-agonist profile at the molecular level.

The researchers used molecular dynamics (MD) simulations to model tirzepatide binding to GLP-1R and GIPR at atomic resolution. They tracked conformational changes in the receptors during activation and inactivation, analyzed binding characteristics at specific residue positions, and performed computational mutation studies to determine how changes in tirzepatide's amino acid sequence affect its affinity for each receptor.

Tirzepatide (Mounjaro/Zepbound) is the first dual GLP-1/GIP agonist to reach the market, but exactly how a single peptide activates two different receptors wasn't fully understood. This study reveals the molecular details — showing which parts of the tirzepatide molecule are responsible for each receptor interaction. This knowledge is essential for designing the next generation of dual and triple agonist peptide drugs.

The success of tirzepatide has sparked a race to develop more multi-receptor agonists — drugs that hit two or three targets at once for greater efficacy. Understanding exactly how tirzepatide binds differently to GLP-1R versus GIPR at the molecular level provides a roadmap for designing next-generation peptides like retatrutide (a triple agonist) and other multi-target drugs in development for obesity and diabetes.

This is entirely a computational study — all findings are based on molecular simulations, not experimental measurements of actual binding or receptor activation. Molecular dynamics simulations depend on force field accuracy and simulation timescales, which may not capture all biologically relevant conformational states. The predictions about mutation effects need experimental validation.